Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
Abstract Immune checkpoint inhibitors (ICIs) have become pivotal in the treatment of lung cancer. An increasing number of immune‐related adverse events (irAEs) have been recognized with their use. To our knowledge, this is the first published case of sarcoid‐like pulmonary lymphadenopathy associated...
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
Wiley
2020-04-01
|
| Colección: | Respirology Case Reports |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1002/rcr2.542 |